http://www.fool.com/News/mft/2006/mft06100206.htm?ref=foolwatchGilead's Smart RiskBy Brian Gorman October 2, 2006 Gilead Sciences' (Nasdaq: GILD) acquisition party rolls on. In its biggest deal yet, the company announced today that it will purchase fellow drug developer Myogen (Nasdaq: MYOG) for $2.5 billion in cash. Gilead's stock is taking a hit at the moment, perhaps because of worry about the acquisition's price tag. However, investors can rest assured that this deal rests on sound thinking......
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Ma